Clinical Trials Logo

Axillary Hyperhidrosis clinical trials

View clinical trials related to Axillary Hyperhidrosis.

Filter by:
  • None
  • Page 1

NCT ID: NCT02295891 Recruiting - Clinical trials for Axillary Hyperhidrosis

Miradry Treatment for Focal Axillary Hyperhidrosis

MiraDry Tx
Start date: November 2014
Phase: N/A
Study type: Interventional

Primary hyperhidrosis is a pathological condition characterized by the idiopathic and excessive secretion of sweat beyond normal physiological demand and is localized at particular foci such as the face, axilla, palms of the hands, and soles of the feet. Patients seeking medical attention for hyperhidrosis often report disruptions to their professional and/or social lives due to sweating and subsequently experience many psychosocial difficulties, such as anxiety, social phobia, and depression. Therefore, a psychiatric explanation of causality is frequently offered for these patients during diagnosis. Excessive sweating is often mistakenly interpreted as a symptom of an anxiety disorder and can be cause for social embarrassment, exacerbating emotional stress and social avoidance. As currently constituted, the treatment of secondary psychosocial symptoms in primary hyperhidrosis is poorly understood and requires further investigation.

NCT ID: NCT02105753 Enrolling by invitation - Clinical trials for Axillary Hyperhidrosis

Tx Axillary Hyperhidrosis 1210nm Diode Laser

Start date: October 2013
Phase: N/A
Study type: Interventional

Primary axillary hyperhidrosis is a common idiopathic disorder of the eccrine sweat glands that interferes with daily activities and causes significant social distress. This pilot study is designed to evaluate the efficacy and histologic effects of the 1210nm diode laser for the treatment of axillary hyperhidrosis. Initial results may inform the design of an anticipated larger prospective controlled trial. Study participants will receive one laser treatment to one randomly-assigned axilla using the 1210 nm diode laser, and two treatments to the opposite axilla. Changes in sweating will be measured both by quantitative gravimetric analysis of sweat production and by expert panel evaluation of photographs of the starch-iodine test performed on each axilla. Participants will also be asked to subjectively classify the severity of their axillary sweating. These measures will be performed at pretreatment and at one, three, and six months following treatment. Biopsies of both axillae will be done before and two weeks after treatment to assess histologic changes to the eccrine gland and surrounding structures. Treatment of axillary hyperhidrosis with the 1210nm diode laser is a novel approach based on the unique absorption characteristics of this wavelength. We hypothesize that selective heating of lipids at the appropriate tissue level will impact adjacent eccrine glands typically seated at the dermo-hypodermal junction, leading to subjective and/or objective decreases in eccrine secretions. This type of treatment may offer an effective, non-invasive and safe alternative to current treatment modalities.

NCT ID: NCT01274611 Completed - Clinical trials for Axillary Hyperhidrosis

Botox and Suction-Curettage for Treatment of Excessive Underarm Sweating (Axillary Hyperhidrosis)

Start date: December 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the effectiveness of two methods in the treatment of excessive underarm sweating (axillary hyperhidrosis): suction-curettage and Botox injections. Suction-curettage is a method in which the doctor will insert a suction tool into two small incisions in order to suction out the sweat-producing glands. It is similar to liposuction, but instead of suctioning out fat, the doctor suctions out the layer of the deep skin where the sweat glands are located. This method has been shown in some studies to effectively reduce underarm sweating for months at a time. Botox is a Food and Drug Administration (FDA) approved drug that in small doses, paralyses muscles. It is most commonly and famously used in the treatment of facial wrinkles. However, it has also been approved to treat excessive sweating. When injected in areas that sweat excessively, sweating can be significantly reduced in that area for months at a time. This study is a pilot study designed to determine feasibility of these procedures.

NCT ID: NCT01118429 Completed - Clinical trials for Axillary Hyperhidrosis

Use of Oxybutynin to Treat Axillary Hyperhidrosis

Start date: January 2007
Phase: N/A
Study type: Interventional

The objective of this study was to evaluate the effectiveness and patient satisfaction with the use of oxybutynin at low doses for treating axillary hyperhidrosis in a large series of patients.

NCT ID: NCT01091129 Completed - Clinical trials for Axillary Hyperhidrosis

Clinical Evaluation of the miraDry System in Subjects With Hyperhidrosis

Start date: February 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether treatment by the miraDry System can safely reduce the severity of axillary hyperhidrosis (excessive underarm sweating).

NCT ID: NCT00735293 Completed - Clinical trials for Axillary Hyperhidrosis

VASER Treatment of Axillary Hyperhidrosis/Bromidrosis

Start date: April 2007
Phase: Phase 4
Study type: Interventional

Patients with excessive underarm odor and sweating and/or odor are treated with the VASER system to determine the VASER's effectiveness in reducing underarm sweat and odor